RU2017131900A3 - - Google Patents

Download PDF

Info

Publication number
RU2017131900A3
RU2017131900A3 RU2017131900A RU2017131900A RU2017131900A3 RU 2017131900 A3 RU2017131900 A3 RU 2017131900A3 RU 2017131900 A RU2017131900 A RU 2017131900A RU 2017131900 A RU2017131900 A RU 2017131900A RU 2017131900 A3 RU2017131900 A3 RU 2017131900A3
Authority
RU
Russia
Application number
RU2017131900A
Other languages
Russian (ru)
Other versions
RU2017131900A (ru
RU2723091C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017131900A publication Critical patent/RU2017131900A/ru
Publication of RU2017131900A3 publication Critical patent/RU2017131900A3/ru
Application granted granted Critical
Publication of RU2723091C2 publication Critical patent/RU2723091C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2017131900A 2015-03-23 2016-02-12 Олигонуклеотидные последовательности, нацеленные на транскрипционный фактор tsc22d4, для лечения резистентности к инсулину RU2723091C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15160259.6A EP3072969A1 (en) 2015-03-23 2015-03-23 Oligonucleotide sequences targeting transcription factor TSC22D4 for the treatment of insulin resistance
EP15160259.6 2015-03-23
PCT/EP2016/053050 WO2016150618A1 (en) 2015-03-23 2016-02-12 Oligonucleotide sequences targeting transcription factor tsc22d4 for the treatment of insulin resistance

Publications (3)

Publication Number Publication Date
RU2017131900A RU2017131900A (ru) 2019-04-23
RU2017131900A3 true RU2017131900A3 (enExample) 2019-06-10
RU2723091C2 RU2723091C2 (ru) 2020-06-08

Family

ID=52784935

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017131900A RU2723091C2 (ru) 2015-03-23 2016-02-12 Олигонуклеотидные последовательности, нацеленные на транскрипционный фактор tsc22d4, для лечения резистентности к инсулину

Country Status (11)

Country Link
US (2) US10676739B2 (enExample)
EP (2) EP3072969A1 (enExample)
JP (1) JP2018513841A (enExample)
KR (1) KR20170128348A (enExample)
CN (1) CN107278229A (enExample)
BR (1) BR112017016021A2 (enExample)
DK (1) DK3274455T3 (enExample)
ES (1) ES2837085T3 (enExample)
MX (1) MX384193B (enExample)
RU (1) RU2723091C2 (enExample)
WO (1) WO2016150618A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7289510B2 (ja) * 2019-05-08 2023-06-12 国立大学法人高知大学 認知症治療薬のスクリーニング方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2377385A1 (en) * 1999-06-03 2000-12-14 Jessie L.S. Au Methods and compositions for modulating cell proliferation and cell death
EP2305813A3 (en) * 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
EP1692521A1 (en) 2003-12-11 2006-08-23 Beth Israel Deaconess Medical Center, Inc. Rbp4 in insulin sensitivity/resistance, diabetes, and obesity
CA2566286A1 (en) * 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
US7943306B2 (en) * 2005-01-12 2011-05-17 The Board Of Trustees Of The Leland Stanford Junior University Gene expression signature for prediction of human cancer progression
US20140227289A1 (en) 2011-05-13 2014-08-14 Stephen Michael Cohen Compounds and methods for treating insulin resistance syndrome
GB201120317D0 (en) 2011-11-24 2012-01-04 Queen Mary & Westfield College Screening method
EP2816356A1 (en) 2013-06-17 2014-12-24 Ruprecht-Karls-Universität Heidelberg Treatment of insulin resistance through inhibitors of transcription factor TSC22D4
RU2573450C1 (ru) * 2014-08-11 2016-01-20 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Способ выявления генов-мишеней для диагностики и терапии лейкозов человека

Also Published As

Publication number Publication date
MX384193B (es) 2025-03-12
EP3274455A1 (en) 2018-01-31
US20180023078A1 (en) 2018-01-25
US20200255834A1 (en) 2020-08-13
EP3072969A1 (en) 2016-09-28
BR112017016021A2 (pt) 2018-03-20
RU2017131900A (ru) 2019-04-23
DK3274455T3 (da) 2020-12-14
EP3274455B1 (en) 2020-10-14
JP2018513841A (ja) 2018-05-31
RU2723091C2 (ru) 2020-06-08
US10676739B2 (en) 2020-06-09
WO2016150618A1 (en) 2016-09-29
CA2979115A1 (en) 2016-09-29
US11053499B2 (en) 2021-07-06
MX2017012231A (es) 2018-01-30
KR20170128348A (ko) 2017-11-22
ES2837085T3 (es) 2021-06-29
CN107278229A (zh) 2017-10-20

Similar Documents

Publication Publication Date Title
BR112018002648A2 (enExample)
BR112018004941A2 (enExample)
AU2022228198B1 (enExample)
CN303069162S (zh) 电气装置盖板
CN303066495S (zh) 喷枪
CN303070853S (zh) 阀门(五)
CN303067902S (zh) 自行车码表(sd-5761)
CN303072233S (zh) 卷烟纸(16)
BE2015C047I2 (enExample)
BE2015C044I2 (enExample)
BR0003208B1 (enExample)
BR0003751B1 (enExample)
BR0007834B1 (enExample)
BR0006634B1 (enExample)
BR0007487B1 (enExample)
BR0000763F1 (enExample)
BR0000695B1 (enExample)
BR122014029722B1 (enExample)
BR0000126B1 (enExample)
BR0008132B1 (enExample)
BR0318696B1 (enExample)
BR0009373B1 (enExample)
BR0009649B1 (enExample)
BR0007747B1 (enExample)
BR0009757B1 (enExample)